MA28179A1 - Nouveau compose, compositions correspondantes, methodes de fabrication et/ou de traitement - Google Patents

Nouveau compose, compositions correspondantes, methodes de fabrication et/ou de traitement

Info

Publication number
MA28179A1
MA28179A1 MA29057A MA29057A MA28179A1 MA 28179 A1 MA28179 A1 MA 28179A1 MA 29057 A MA29057 A MA 29057A MA 29057 A MA29057 A MA 29057A MA 28179 A1 MA28179 A1 MA 28179A1
Authority
MA
Morocco
Prior art keywords
methods
making
processing
new compound
preparation
Prior art date
Application number
MA29057A
Other languages
English (en)
Inventor
Orco Philip C Dell
Ann Marie Diederich
Qiaogang Su
Jeffrey Lee Wood
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA28179A1 publication Critical patent/MA28179A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composé nouveau, compositions correspondantes, procédés de préparation et/ou méthodes de traitement II est présenté une forme cristalline nouvelle de pentahydrate de monochlorhydrate de topotécan qui est un pentahydrate de monochrlohydrate de 10[(diméthyl-amino)méthyl] -4-éthyl-4, 9-dihydroxy- lH-pyrano [31 , 4 ' :6,7] -indolizino[1,2-b]quinoléine-3,14(4H, 12H)dione, des compo¬sitions pharmaceutiques correspondantes, des procédés pour leur préparation et/ou des méthodes pour leur utilisation à des fins de traitement de maladies virales et/ou en rapport avec le cancer.
MA29057A 2003-11-12 2006-05-24 Nouveau compose, compositions correspondantes, methodes de fabrication et/ou de traitement MA28179A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51916003P 2003-11-12 2003-11-12
US52457403P 2003-11-24 2003-11-24

Publications (1)

Publication Number Publication Date
MA28179A1 true MA28179A1 (fr) 2006-09-01

Family

ID=34594951

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29057A MA28179A1 (fr) 2003-11-12 2006-05-24 Nouveau compose, compositions correspondantes, methodes de fabrication et/ou de traitement

Country Status (16)

Country Link
US (2) US7754733B2 (fr)
EP (1) EP1689400A4 (fr)
JP (1) JP2007510751A (fr)
KR (1) KR20060122847A (fr)
CN (1) CN1913897B (fr)
AR (1) AR046579A1 (fr)
AU (1) AU2004289318B2 (fr)
BR (1) BRPI0416366A (fr)
CA (1) CA2545876A1 (fr)
IL (1) IL175369A (fr)
IS (1) IS8491A (fr)
MA (1) MA28179A1 (fr)
NO (1) NO20062616L (fr)
RU (1) RU2352572C2 (fr)
TW (1) TWI333492B (fr)
WO (1) WO2005046608A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI333492B (en) * 2003-11-12 2010-11-21 Smithkline Beecham Cork Ltd Crystalline topotecan hydrochloride product and preparation thereof
US8349863B2 (en) 2005-10-10 2013-01-08 Cipla Limited Crystalline polymorphic form of a camptothecin analogue
US7547785B2 (en) * 2005-12-26 2009-06-16 Dr. Reddy's Laboratories Limited Process for preparing topotecan
US7977483B2 (en) 2007-04-11 2011-07-12 Scinopharm Taiwan, Ltd. Process for making topotecan
WO2008130534A1 (fr) * 2007-04-19 2008-10-30 Scinopharm Taiwan Ltd. Formes cristallines de chlorhydrate de topotécan et leurs procédés de préparation
US7572803B2 (en) * 2007-10-25 2009-08-11 The Christus Stehlin Foundation For Cancer Research Hydrated crystalline esters of camptothecin
ITMI20072268A1 (it) 2007-12-04 2009-06-05 Antibioticos Spa Polimorfi cristallini di topotecan cloridrato con elevato grado di purezza e metodi per la loro preparazione
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
FI931384A7 (fi) * 1990-09-28 1993-03-26 Smithkline Beecham Corp Vesiliukoisia kamptotekiinianalogeja, prosesseja ja menetelmiä
FR2790261B1 (fr) * 1999-02-26 2004-09-10 Sod Conseils Rech Applic Nouveaux analogues optiquement purs de la camptothecine et leurs procedes de preparation
FR2757514B1 (fr) * 1996-12-20 1999-02-12 Sod Conseils Rech Applic Nouveaux analogues de la camptothecine, des procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
ES2180063T3 (es) * 1996-12-19 2003-02-01 Reddys Lab Ltd Dr Analogos de 20(s)-camptotecina en el anillo c solubles en agua.
AR013261A1 (es) * 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
EP1430059B1 (fr) 2001-09-25 2006-03-01 Dr. Reddy's Laboratories Ltd. Sels acceptables d'un point de vue pharmaceutique de 20(s)-camptothecines
US6756381B2 (en) * 2002-02-21 2004-06-29 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
TWI333492B (en) * 2003-11-12 2010-11-21 Smithkline Beecham Cork Ltd Crystalline topotecan hydrochloride product and preparation thereof
US8349863B2 (en) * 2005-10-10 2013-01-08 Cipla Limited Crystalline polymorphic form of a camptothecin analogue
US7547785B2 (en) * 2005-12-26 2009-06-16 Dr. Reddy's Laboratories Limited Process for preparing topotecan
WO2008130534A1 (fr) 2007-04-19 2008-10-30 Scinopharm Taiwan Ltd. Formes cristallines de chlorhydrate de topotécan et leurs procédés de préparation
ITMI20072268A1 (it) * 2007-12-04 2009-06-05 Antibioticos Spa Polimorfi cristallini di topotecan cloridrato con elevato grado di purezza e metodi per la loro preparazione

Also Published As

Publication number Publication date
IS8491A (is) 2006-05-30
TWI333492B (en) 2010-11-21
RU2352572C2 (ru) 2009-04-20
US8158645B2 (en) 2012-04-17
US20070117832A1 (en) 2007-05-24
WO2005046608B1 (fr) 2005-12-29
RU2006120422A (ru) 2007-12-27
WO2005046608A2 (fr) 2005-05-26
TW200530250A (en) 2005-09-16
AR046579A1 (es) 2005-12-14
US20100210677A1 (en) 2010-08-19
CA2545876A1 (fr) 2005-05-26
CN1913897A (zh) 2007-02-14
US7754733B2 (en) 2010-07-13
AU2004289318B2 (en) 2010-04-29
AU2004289318A1 (en) 2005-05-26
IL175369A (en) 2012-03-29
EP1689400A4 (fr) 2006-12-27
EP1689400A2 (fr) 2006-08-16
BRPI0416366A (pt) 2007-03-13
IL175369A0 (en) 2008-04-13
NO20062616L (no) 2006-07-12
CN1913897B (zh) 2010-08-11
JP2007510751A (ja) 2007-04-26
KR20060122847A (ko) 2006-11-30
WO2005046608A3 (fr) 2005-11-03

Similar Documents

Publication Publication Date Title
HUP0400203A3 (en) Use of combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases, for preparation of pharmaceutical compositions
WO2005049581A8 (fr) Derives de pyridazine-3(2h)-ones et utilisation en tant qu'inhibiteurs de pde4
IL174475A0 (en) 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo['2,3-c]pyridin-2-ylmethyl)pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes
WO2002053140A3 (fr) Nouvelles combinaisons medicamenteuses
ES2195785A1 (es) Nuevos derivados de piridazin-3(2h)-ona.
WO2006029146A3 (fr) 6h-[1]benzopyrano[4,3-b]quinolines et leur utilisation comme agents oestrogenes
CA2503767A1 (fr) Pyridopyrrolizine et derives de pyridoindolizine
IL164974A0 (en) Novel compounds and their use
ID25856A (id) Senyawa-senyawa baru
HUP0204143A2 (en) Tricyclic 1-benzylpyrazoles-3-carboxylic acid derivatives, preparation of the compounds, their use and pharmaceutical compositions containing them
JP2002520273A5 (fr)
MA28179A1 (fr) Nouveau compose, compositions correspondantes, methodes de fabrication et/ou de traitement
GT200200081A (es) Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11.0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma
WO2005056551A3 (fr) Nouveaux derives du 2-hydroxytetrahydrofuranne et leur application a titre de medicaments
GB0322510D0 (en) Novel compounds
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
JP2004538278A5 (fr)
AU2002256334A1 (en) Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino(2,3-f)quinoxaline
WO2005013935A3 (fr) Nouvelle composition
WO2003045940A3 (fr) Composes therapeutiques
DE60111553D1 (de) Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
WO2003045917A3 (fr) Antagonistes vii du recepteur ccr3
WO2003045952A3 (fr) Composes hexacycliques
SE0100297D0 (sv) New compounds
SE0100296D0 (sv) New compounds